title: Cellular therapy and induced neuronal replacement for Huntington's disease.
abstract: Huntington's disease (HD) is an inherited, relentlessly progressive neurodegenerative disease with an invariably fatal outcome. HD is inherited in an autosomal dominant fashion, and is characterized pathologically by the loss of cortical and striatal neurons, and clinically by involuntary choreiform movements accompanied by progressive cognitive impairment and emotional lability. The disorder is caused by an expanded cystosine adenine guanine (CAG) tri-nucleotide repeat encoding polyglutamine (polyQ) in the first exon of the Huntingtin gene. There is a correlation between the number of CAG repeats and disease onset, such that in patients with CAG repeat lengths of 36 to 60, disease symptoms typically manifest after 35 years of age, whereas CAG repeat lengths >60 yield the more severe juvenile form of the disease. Even though mutant huntingtin is expressed throughout the brain, it is characterized by the selective degeneration of medium spiny neurons of the caudate and putamen, which heralds more widespread neuronal degeneration with disease progression. The mechanisms of cell dysfunction and death in HD have been the subjects of a number of studies, which have led to therapeutic strategies largely based on the amelioration of mutant huntingtin-related metabolic impairment and cellular toxicity. Each of these approaches has aimed to delay or stop the preferential degeneration of medium spiny neurons early in the disease course. Yet, in later stages of the disease, after cell death has become prominent, cell replacement therapy (whether by direct cell transplantation or by the mobilization of endogenous progenitors) may comprise a stronger potential avenue for therapy. In this review, we will consider recent progress in the transplantation of fetal striatal cells to the HD brain, as well as emerging alternative sources for human striatal progenitor cells. We will then consider the potential application of gene therapy toward the induction of striatal neurogenesis and neuronal recruitment, with an eye toward its potential therapeutic use in HD.
authors.affiliation: Department of Neurology, Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, NY, USA. Abdellatif_Benraiss@URMC.Rochester.edu
authors.forename: Abdellatif
authors.initials: A
authors.lastname: Benraiss
authors.forename: Steven A
authors.initials: SA
authors.lastname: Goldman
mesh_terms: D000818:Animals; D019485:Bone Morphogenetic Proteins / Q000378:metabolism; D001921:Brain / Q000166:cytology / Q000196:embryology; D017690:Cell Transplantation / Q000379:methods*; D053595:Embryonic Stem Cells / Q000502:physiology / Q000637:transplantation; D006801:Humans; D006816:Huntington Disease / Q000503:physiopathology / Q000601:surgery*; D009474:Neurons / Q000502:physiology*; D039904:Pluripotent Stem Cells / Q000502:physiology / Q000637:transplantation
chemical_list: D019485:Bone Morphogenetic Proteins